Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04238819




Registration number
NCT04238819
Ethics application status
Date submitted
22/01/2020
Date registered
23/01/2020
Date last updated
6/05/2024

Titles & IDs
Public title
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Scientific title
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
Secondary ID [1] 0 0
I3Y-MC-JPCS
Secondary ID [2] 0 0
16950
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Relapsed Solid Tumor 0 0
Refractory Solid Tumor 0 0
Condition category
Condition code
Cancer 0 0 0 0
Neuroendocrine tumour (NET)
Cancer 0 0 0 0
Children's - Other

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Abemaciclib
Treatment: Drugs - Irinotecan
Treatment: Drugs - Temozolomide
Treatment: Drugs - Dinutuximab
Treatment: Drugs - GM-CSF

Experimental: Dose Escalation: Abemaciclib + Irinotecan + Temozolomide - Abemaciclib given orally, irinotecan given intravenously (IV) and temozolomide given orally.

Experimental: Dose Expansion: Abemaciclib + Irinotecan + Temozolomide - Abemaciclib given orally, irinotecan given IV and temozolomide given orally.

Experimental: Dose Escalation: Abemaciclib + Temozolomide - Abemaciclib and temozolomide given orally.

Experimental: Dose Expansion: Abemaciclib + Temozolomide - Abemaciclib and temozolomide given orally.

Experimental: Part C Stage 1: Abemaciclib in Combination with Dinutuximab, GM-CSF, Irinotecan, and Temozolomide - Abemaciclib given orally, dinutuximab given IV, granulocyte macrophage colony-stimulating factor (GM-CSF) given subcutaneously (subQ), irinotecan given IV and temozolomide given orally or IV.

Experimental: Part C Stage 2: Abemaciclib in Combination with Dinutuximab, GM-CSF, Irinotecan, and Temozolomide - Abemaciclib given orally, dinutuximab given IV, GM-CSF given subQ, irinotecan given IV and temozolomide given orally or IV.


Treatment: Drugs: Abemaciclib
Administered orally

Treatment: Drugs: Irinotecan
Administered IV

Treatment: Drugs: Temozolomide
Administered orally or IV

Treatment: Drugs: Dinutuximab
Administered IV

Treatment: Drugs: GM-CSF
Administered subQ
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number or Participants with Dose Limiting Toxicities (DLTs)
Timepoint [1] 0 0
Cycle 1 (21 Day Cycle)
Primary outcome [2] 0 0
Pharmacokinetics (PK): Mean Steady State Concentrations of Abemaciclib
Timepoint [2] 0 0
Cycle 1 through Cycle 3 (21 Day Cycle)
Primary outcome [3] 0 0
PK: Mean Steady State Concentrations of Irinotecan
Timepoint [3] 0 0
Cycle 1 through Cycle 3 (21 Day Cycle)
Primary outcome [4] 0 0
PK: Mean Steady State Concentrations of Temozolomide
Timepoint [4] 0 0
Cycle 1 through Cycle 3 (21 Day Cycle)
Primary outcome [5] 0 0
Objective Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR), Partial Response (PR), or Minimal Response (MR): Part C, only
Timepoint [5] 0 0
Baseline through Disease Progression or Death (Estimated up to 24 Months)
Secondary outcome [1] 0 0
Overall Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR) or Partial Response (PR): Parts A and B, only
Timepoint [1] 0 0
Baseline through Disease Progression or Death (Estimated up to 24 Months)
Secondary outcome [2] 0 0
Duration of Response (DoR)
Timepoint [2] 0 0
Date of First Evidence of a CR, PR, or MR (Part C, only) to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 24 Months)
Secondary outcome [3] 0 0
Clinical Benefit Rate (CBR): Percentage of Participants with Best Overall Response of CR, PR, MR (Part C, only) or SD With a Duration of At Least 6 Months
Timepoint [3] 0 0
Baseline through Disease Progression or Death Due to Any Cause (Estimated up to 24 Months)
Secondary outcome [4] 0 0
Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response of CR, PR, MR (Part C, only), and Stable Disease (SD)
Timepoint [4] 0 0
Baseline through Measured Progressive Disease (Estimated up to 24 Months)
Secondary outcome [5] 0 0
Progression-Free Survival (PFS): Part C, Only
Timepoint [5] 0 0
Baseline through Progressive Disease or Death (Estimated up to 24 Months)
Secondary outcome [6] 0 0
Acceptability Questionnaire
Timepoint [6] 0 0
Cycle 2 Day 1 (21 Day Cycles)

Eligibility
Key inclusion criteria
- Parts A and B only:

- Participants must be less than or equal to (=)18 years of age.

- Body weight greater than or equal to (=)10 kilograms and body surface area (BSA)
=0.5

- Participants with any relapsed/refractory malignant solid tumor (excluding
lymphoma), including central nervous system tumors, that have progressed on
standard therapies.

- For sites that are actively enrolling Parts B and C, participants with
neuroblastoma who are eligible for Part C will be excluded from Part B unless
approved by Lilly CRP/CRS.

- Part C only:

- Participants must be less than (<) 21 years of age.

- Participants have a BSA =0.2 m².

- Participants with first relapse/refractory neuroblastoma.

- All Parts

- Participants must have measurable or evaluable disease by RECIST v1.1 or RANO.

- A Lansky score =50 for participants <16 years of age or Karnofsky score =50 for
participants =16 years of age.

- Participants must have discontinued all previous treatments for cancer or
investigational agents and must have recovered from the acute effects to Grade =1
at the time of enrollment.

- Able to swallow and/or have a gastric/nasogastric tube.

- Adequate hematologic and organ function =2 weeks (14 days) prior to first dose of
study drug.

- Females of reproductive potential must have negative urine or serum pregnancy
test at baseline (within 7 days prior to starting treatment).

- Female participants of reproductive potential must agree to use highly effective
contraceptive precautions during the trial. For abemaciclib, females should use
contraception for at least 3 weeks following the last abemaciclib. For other
study drugs, highly effective contraceptive precautions (and avoiding sperm
donation) must be used according to their label.

- Life expectancy of at least 8 weeks and able to complete at least 1 cycle of
treatment.

- Caregivers and participants willing to make themselves available for the duration
of the trial.
Minimum age
No limit
Maximum age
21 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Received allogenic bone marrow or solid organ transplant.

- Received live vaccination.

- Intolerability or hypersensitivity to any of the study treatments or its components.

- Diagnosed and/or treated additional malignancy within 3 years prior to enrollment that
may affect the interpretation of results, with the exception of curatively treated
basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or
curatively resected in situ cervical and/or breast cancers.

- Pregnant or breastfeeding.

- Active systemic infections.

- Serious and/or uncontrolled preexisting medical condition(s) that would preclude
participation in this study.

- Parts A and C only: Have a bowel obstruction.

- Prior treatment with drugs known to be strong inhibitors or inducers of isoenzyme
cytochrome P450 3A (CYP3A) or strong inhibitors of uridine diphosphate-glucuronosyl
transferase 1A1 (UGT1A1) if the treatment cannot be discontinued or switched to a
different medication at least 5 half-lives prior to starting study drug.

- Received prior treatment with cyclin-dependent kinase (CDK) 4 & 6 inhibitor.

- Part C only: Received prior systemic therapy for relapsed/refractory neuroblastoma.

- Part C only, have received prior anti-GD2 therapy during induction phase.

- Currently enrolled in any other clinical study involving an investigational product or
non-approved use of a drug or device.

- Has received an experimental treatment in a clinical trial within the last 30 days or
5 half-lives, whichever is longer.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/11/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/10/2028
Actual
Sample size
Target
117
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Recruitment hospital [1] 0 0
The Children's Hospital at Westmead - Westmead
Recruitment hospital [2] 0 0
Royal Children's Hospital - Melbourne
Recruitment hospital [3] 0 0
Perth Children's Hospital - Perth
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment postcode(s) [2] 0 0
3052 - Melbourne
Recruitment postcode(s) [3] 0 0
6009 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Nebraska
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Ohio
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
Rhode Island
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Utah
Country [18] 0 0
Belgium
State/province [18] 0 0
Oost-Vlaanderen
Country [19] 0 0
Canada
State/province [19] 0 0
Ontario
Country [20] 0 0
Canada
State/province [20] 0 0
Quebec
Country [21] 0 0
France
State/province [21] 0 0
Rhône
Country [22] 0 0
France
State/province [22] 0 0
Val-de-Marne
Country [23] 0 0
France
State/province [23] 0 0
Paris
Country [24] 0 0
Germany
State/province [24] 0 0
Baden-Württemberg
Country [25] 0 0
Germany
State/province [25] 0 0
Nordrhein-Westfalen
Country [26] 0 0
Germany
State/province [26] 0 0
Berlin
Country [27] 0 0
Italy
State/province [27] 0 0
Lazio
Country [28] 0 0
Spain
State/province [28] 0 0
Barcelona [Barcelona]
Country [29] 0 0
Spain
State/province [29] 0 0
Madrid, Comunidad De
Country [30] 0 0
Spain
State/province [30] 0 0
València

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with
other drugs to kill cancer cells. The study is open to children and young adults with solid
tumors, including neuroblastoma, that did not respond or grew during other anti-cancer
treatment. For each participant, the study is estimated to last up to 2 years.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04238819
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries